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for the non-surgical management of knee osteoarthritis’”We thank Prof. du Souich for commending the 2014 guidelines
for the management of knee OA for taking into account the role
of co-morbidities in its treatment recommendations1 and whole-
heartedly share his views on the importance of considering co-
morbidities and the risk of drugedrug interactions in those with
multiple morbidity. Indeed, our decision to formulate treatment
guidelines more tailored to patient characteristics was predicated
on these important issues. Prof. du Souich’s emphasis on safety in
treating at-risk individuals resonateswith our own view, and, taken
together with reliable data supporting their effectiveness, is the ba-
sis for our emphasis on non-pharmacological interventions for pa-
tients in the high risk group, namely strength training and aerobic
exercise (land-based or water-based), weight management, biome-
chanical interventions, and self-management and education.
The paucity of reliable data to support the effectiveness of phar-
macological treatments, and concerns about safety, resulted in only
intra-articular corticosteroids, COX-2 inhibitors and duloxetine
receiving designations of ‘appropriate’. As Prof. du Souich points
out, all pharmaceuticals carry some risk, and so implementation
of our recommendations ultimately remains a shared decision be-
tween the prescribing physician and the patient, taking into ac-
count individual characteristics and preferences.
Prof. du Souich advocates for incorporation of chondroitin sul-
fate and glucosamine sulfate into the knee OA treatment guidelines
for at risk individuals, a view based on the undisputed safety proﬁle
of these products, and also selected efﬁcacy data. However, the
OARSI recommendations are a synthesis of the best available evi-
dence in the context of all available treatment alternatives, by
health professionals with diverse expertise. An ‘uncertain’ designa-
tion does not mean that an intervention, e.g. glucosamine or chon-
droitin, should not be used. Individual clinicians and patients might
reasonably choose to use such treatments; they should however do
this cognizant of the strength of the underpinning evidence.
The development of guidelines requires a tremendous effort in
synthesizing a large evidence base that is continually expanding.
As such, one of the main objectives should be to highlight
evidence-gaps and stimulate dialog, which Prof. du Souich has
kindly provided. Such areas include the management of OA in pa-
tients with multiple morbidities and the approach to balancing
beneﬁts and harms. When pharmacological treatment is indicated,
we agreewith Prof. du Souich’s statement that, ‘clinicians should be
advised to start symptomatic treatment with the drugs with the
[smallest] potential to harm the patient’. Nevertheless, non-DOI of original article: http://dx.doi.org/10.1016/j.joca.2014.01.003.
http://dx.doi.org/10.1016/j.joca.2014.04.001
1063-4584/ 2014 Published by Elsevier Ltd on behalf of Osteoarthritis Research Societpharmacological modalities should be preferred and proposed ﬁrst
to the patient, considering the patient’s preference.
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